Jazz Pharmaceuticals raises 2026 revenue outlook after Q3 earnings
Jazz Pharmaceuticals reported third-quarter 2026 revenue of $1.2B, up 10% year over year, and raised 2026 revenue guidance to $4.775B-$4.85B. The quarter included the launch of Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma and completion of the Actio acquisition. Jazz also reported a GAAP net loss of $483.4M for the quarter.
Why it matters
The higher revenue range gives investors an updated framework for Jazz's 2026 sales outlook. The Ziihera launch and Actio transaction expand the company's commercial and rare-epilepsy pipeline exposure, while the reported loss highlights the earnings effect of acquisition-related and development costs.
Key facts
- 1Xywav net product sales rose 12% year over year to $483 million in 3Q26. sec.gov
- 2Ziihera generated $21 million in 3Q26 sales after receiving FDA approval on August 25, 2026. sec.gov
- 3Jazz completed its Actio acquisition in September 2026, adding ABS-1230 (JZP6979) to its rare-epilepsy portfolio. sec.gov
- 4The company generated $1.3 billion in cash from operations during the first nine months of 2026. sec.gov
- 5Jazz reported a GAAP net loss of $483.4M in Q3 2026. stocktitan.net
Open questions
- The Actio purchase price of $820M appears in one earnings recap but is not confirmed in the company materials provided.
- The materials report different EPS figures, including a $-3.88 figure and a $7.48 per-share loss, without consistently identifying the same accounting basis.
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.